open access

Vol 16, No 1 (2013)
Original articles
Published online: 2013-02-08
Submitted: 2013-02-08
Accepted: 2013-02-08
Get Citation

Role of F18-FDG-PET/CT in restaging patients affected by renal carcinoma

Francesco Bertagna, Federica Motta, Mattia Bertoli, Giovanni Bosio, Simona Fisogni, Regina Tardanico, Vittorio Ferrari, Alessandro Antonelli, Claudio Simeone, Sergio Cosciani Cunico, Raffaele Giubbini
DOI: 10.5603/NMR.2013.0002
·
Nucl. Med. Rev 2013;16(1):3-8.

open access

Vol 16, No 1 (2013)
Original articles
Published online: 2013-02-08
Submitted: 2013-02-08
Accepted: 2013-02-08

Abstract

ACKGROUND: Renalcancers account for around 3% of all
cancers and the most common type of (90%) is renal cell carcinoma
Five-year survival rate in renal cancer patients is 68.4%.
AIM: The aim of our study was to establish the role of
F18-FDG-PET/CT in restaging patients with renal carcinoma who
underwent partial or radical nephrectomy. Secondary aim of the
study was to identify histological characteristics of the primary
tumour that may be responsible for the metabolic behaviour of
neoplastic lesions.

MATERIALS AND METHODS:We retrospectively evaluated
68 patients with renal carcinoma in whom F18-FDG-PET/CT
was performed.


RESULTS: Sensitivity, specificity, positive predictive value,
negative predictive value and accuracy of F18-FDG PET/CT were
82%, 100%, 100%, 66.7% and 86.8%, respectively.


CONCLUSIONS: The results of our study suggest that F18-FDG
PET/CT is characterised by high specificity and positive predictive
value and can be useful in restaging patients affected by renal carcinoma. However, due to low negative predictive value,
this method cannot be recommended for definitely ruling out
suspected disease relapse.

Abstract

ACKGROUND: Renalcancers account for around 3% of all
cancers and the most common type of (90%) is renal cell carcinoma
Five-year survival rate in renal cancer patients is 68.4%.
AIM: The aim of our study was to establish the role of
F18-FDG-PET/CT in restaging patients with renal carcinoma who
underwent partial or radical nephrectomy. Secondary aim of the
study was to identify histological characteristics of the primary
tumour that may be responsible for the metabolic behaviour of
neoplastic lesions.

MATERIALS AND METHODS:We retrospectively evaluated
68 patients with renal carcinoma in whom F18-FDG-PET/CT
was performed.


RESULTS: Sensitivity, specificity, positive predictive value,
negative predictive value and accuracy of F18-FDG PET/CT were
82%, 100%, 100%, 66.7% and 86.8%, respectively.


CONCLUSIONS: The results of our study suggest that F18-FDG
PET/CT is characterised by high specificity and positive predictive
value and can be useful in restaging patients affected by renal carcinoma. However, due to low negative predictive value,
this method cannot be recommended for definitely ruling out
suspected disease relapse.

Get Citation

Keywords

PET/CT; F18-FDG; renal cell carcinoma

About this article
Title

Role of F18-FDG-PET/CT in restaging patients affected by renal carcinoma

Journal

Nuclear Medicine Review

Issue

Vol 16, No 1 (2013)

Pages

3-8

Published online

2013-02-08

DOI

10.5603/NMR.2013.0002

Bibliographic record

Nucl. Med. Rev 2013;16(1):3-8.

Keywords

PET/CT
F18-FDG
renal cell carcinoma

Authors

Francesco Bertagna
Federica Motta
Mattia Bertoli
Giovanni Bosio
Simona Fisogni
Regina Tardanico
Vittorio Ferrari
Alessandro Antonelli
Claudio Simeone
Sergio Cosciani Cunico
Raffaele Giubbini

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl